MediWound (NASDAQ:MDWD) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened

MediWound Ltd. (NASDAQ:MDWD) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $16.11 and traded as low as $14.17. MediWound shares last traded at $14.19, with a volume of 65,589 shares changing hands.

Wall Street Analysts Forecast Growth

MDWD has been the subject of several analyst reports. Oppenheimer restated an “outperform” rating and issued a $32.00 target price (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of MediWound in a research report on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research note on Friday, July 17th. Finally, Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, May 30th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $34.00.

MediWound Stock Down 0.8%

The company has a 50-day moving average price of $14.38 and a 200-day moving average price of $16.11. The company has a market capitalization of $182.34 million, a price-to-earnings ratio of -6.28 and a beta of 0.15.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.42. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.The business had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $3.37 million. During the same quarter in the previous year, the firm earned ($0.07) EPS. Equities analysts expect that MediWound Ltd. will post -2.31 EPS for the current fiscal year.

Insider Buying and Selling

In other MediWound news, Director David Morton Fox purchased 3,537 shares of the company’s stock in a transaction on Monday, June 1st. The shares were bought at an average cost of $14.11 per share, with a total value of $49,907.07. Following the transaction, the director directly owned 22,283 shares in the company, valued at approximately $314,413.13. This represents a 18.87% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 9.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On MediWound

Several hedge funds have recently modified their holdings of MDWD. Rhumbline Advisers raised its position in shares of MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 481 shares during the last quarter. Russell Investments Group Ltd. grew its position in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares in the last quarter. BNP Paribas Financial Markets increased its stake in MediWound by 90.4% during the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 723 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 999 shares during the period. Finally, Quarry LP acquired a new position in MediWound in the 4th quarter valued at approximately $26,000. 46.83% of the stock is owned by institutional investors.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.